|
|
| | H-GLY-PRO-GLY-NH2 HCL Basic information |
| Product Name: | H-GLY-PRO-GLY-NH2 HCL | | Synonyms: | H-GLY-PRO-GLY-NH2 HCL;H-Gly-Pro-Gly-NH2;H-Gly-Pro-Gly-NH2 hydrochloride;GPG-NH2;Glycinamide, glycyl-L-prolyl-;Glycyl-L-prolylglycinamide | | CAS: | 141497-12-3 | | MF: | C9H16N4O3 | | MW: | 228.25 | | EINECS: | | | Product Categories: | | | Mol File: | 141497-12-3.mol |  |
| | H-GLY-PRO-GLY-NH2 HCL Chemical Properties |
| Boiling point | 618.0±55.0 °C(Predicted) | | density | 1.326±0.06 g/cm3(Predicted) | | storage temp. | -15°C | | pka | 14.27±0.20(Predicted) | | Sequence | H-Gly-Pro-Gly-NH2 · HCl |
| | H-GLY-PRO-GLY-NH2 HCL Usage And Synthesis |
| Uses | H-Gly-Pro-Gly-NH2 is a tripeptide that inhibits HIV-1 replication. H-Gly-Pro-Gly-NH2 inhibits the activity of HIV-1 IIIB and HIV-2 ROD with EC50 values of 35 μM and 30 μM, respectively. H-Gly Pro Gly NH2 inhibits HIV-1 replication in vitro by interfering with capsid formation. H-Gly Pro Gly NH2 has antiviral activity and can be used for virus research[1][2][3]. | | IC 50 | HIV (IIIB): 35 μM (EC50); HIV-2 (ROD): 30 μM (EC50) | | References | [1] Hglund S, et al. Tripeptide interference with human immunodeficiency virus type 1 morphogenesis. Antimicrob Agents Chemother. 2002 Nov;46(11):3597-605. DOI:10.1128/AAC.46.11.3597-3605.2002 [2] Andersson E, et al. No cross-resistance or selection of HIV-1 resistant mutants in vitro to the antiretroviral tripeptide glycyl-prolyl-glycine-amide[J]. Antiviral research, 2004, 61(2): 119-124. [3] Balzarini J, et al. Obligatory involvement of CD26/dipeptidyl peptidase IV in the activation of the antiretroviral tripeptide glycylprolylglycinamide (GPG-NH(2)). Int J Biochem Cell Biol. 2004 Sep;36(9):1848-59. DOI:10.1016/j.biocel.2004.02.017 |
| | H-GLY-PRO-GLY-NH2 HCL Preparation Products And Raw materials |
|